




Form PTO-14		U.S. Department of Patent and Trademark Office		Atty. Docket No. 575-55873-C/ JPW/AJM/AAB		Serial No. 10/666,513							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) Ann Marie Schmidt, et al.									
				Filing Date September 19, 2003		Group Art Unit							
U.S. PATENT DOCUMENTS													
Examiner Initials		Document Number		Date	Name	Class	Subclass	Filing Date If Appropriate					
<i>AM</i>		5	6	8	8	6	5	3	11/18/97	Ulrich, et al.	-	-	
		5	8	6	4	0	1	8	1/26/99	Morser, et al.	-	-	
		5	9	7	6	8	3	2	11/2/99	Hitomi, et al.	-	-	
FOREIGN PATENT DOCUMENTS													
		Document Number		Date	Country	Class	Subclass	Translation					
								Yes	No				
<i>AM</i>	WO	9	7	3	9	1	2	1	10/23/97	PCT	-	-	
	WO	9	7	3	9	1	2	5	10/23/97	PCT	-	-	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
<i>AM</i>		Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;											
		Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio <i>in vitro</i> and <i>in vivo</i> . Neuron 17: 1005-1013;											
		Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;											
		Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;											
		Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516;											
		Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;											
EXAMINER		DATE CONSIDERED											
<i>AM</i>		-8.19.04											
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Am	Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
	Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313;
	Fu, M-X., et al. (1996). The advanced glycation end product, N ^ε -(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
	Giardino, I., et al. (1994). Nonenzymatic glycosylation <i>in vitro</i> and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693.;
	Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AN	Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin J. Biol. Chem. 270: 25752-25761;
	Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200;
	Kuo, Y-M., et al. (1996). Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081;
	Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21 ^{ras} dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814;
	Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619;

EXAMINER

DATE CONSIDERED

8-19-04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506;
Lorenzo, A. and B.A. Yanker (1994). β -amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Nat. Acad. Sci. USA 91: 12243-12247;
Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224;
Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β 2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094;

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
	Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
	Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
	Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Reddy, S., et al. (1995). N ^c -(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;
	Rénard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;
	Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;
	Roher, A. E., et al. (1996). Morphology and toxicity of A β -(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;
	Schleicher, E. D., et al. (1997). Increased accumulation of the glycooxidation product N ^c -(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403;
	Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
	Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997;
	Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
	Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
	Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
	Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
	Sell, D., et al. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-C/
JPW/AJM/AABSerial No.
10/666,513Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243;
	Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8): #4139;
	Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 575-55873-C/ JPW/AJM/AAB	Serial No. 10/666,513
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) Ann Marie Schmidt, et al.	
				Filing Date September 19, 2003	Group Art Unit

U.S. PATENT DOCUMENTS									
Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate			

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation			
						Yes	No		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
	Yan, S. D., et al. (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
	Yan, S. D., et al. (1997). Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301;

EXAMINER 	DATE CONSIDERED 8-19-04
--------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.